Education
About Us
Working with TipRanks
Follow Us
Tourmaline Bio, Inc. (TRML)
:TRML
TRML Stock Chart & Stats
$47.98
-$0.01(-0.05%)
At close: 4:00 PM EST
$47.98
-$0.01(-0.05%)
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
Volume43.44K
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$239.23M
Total Debt (Recent Filing)$145.00K
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Nov 06, 2025EPS Estimate
-0.91Last Dividend Ex-Date
Oct 20, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AcquisitionNovartis has a definitive agreement to acquire TRML for approximately $1.4 billion, reflecting a strong valuation of the company.
Clinical TrialsPositive topline data from the Phase 2 TRANQUILITY study of Tourmaline's lead asset, pacibekitug, shows statistically significant reductions in inflammation markers.
Strategic ValueThe acquisition complements NVS current extensive CV pipeline by adding a Ph3–ready program with differentiated MOA and advantageous quarterly dosing.
Bears Say
RisksRisks include failure of pacibekitug in clinical trials, regulatory approval, commercial success, and failure to complete the acquisition.
Stock Rating DowngradeThe stock rating for TRML has been downgraded to Market Perform from Outperform.
Tourmaline Bio News
TRML FAQ
What was Tourmaline Bio, Inc.’s price range in the past 12 months?
Currently, no data Available
What is Tourmaline Bio, Inc.’s market cap?
Currently, no data Available
When is Tourmaline Bio, Inc.’s upcoming earnings report date?
Tourmaline Bio, Inc.’s upcoming earnings report date is Nov 06, 2025 which is 2 days ago.
How were Tourmaline Bio, Inc.’s earnings last quarter?
Tourmaline Bio, Inc. released its earnings results on Aug 13, 2025. The company reported -$0.9 earnings per share for the quarter, beating the consensus estimate of -$0.923 by $0.023.
Is Tourmaline Bio, Inc. overvalued?
According to Wall Street analysts Tourmaline Bio, Inc.’s price is currently Overvalued.
Does Tourmaline Bio, Inc. pay dividends?
Tourmaline Bio, Inc. pays a Notavailable dividend of $15.118 which represents an annual dividend yield of N/A. See more information on Tourmaline Bio, Inc. dividends here
What is Tourmaline Bio, Inc.’s EPS estimate?
Tourmaline Bio, Inc.’s EPS estimate is -0.91.
How many shares outstanding does Tourmaline Bio, Inc. have?
Currently, no data Available
What happened to Tourmaline Bio, Inc.’s price movement after its last earnings report?
Tourmaline Bio, Inc. reported an EPS of -$0.9 in its last earnings report, beating expectations of -$0.923. Following the earnings report the stock price went up 3.445%.
Which hedge fund is a major shareholder of Tourmaline Bio, Inc.?
Currently, no hedge funds are holding shares in TRML
Company Description
Tourmaline Bio, Inc.
Tourmaline Bio (TRML) is a biotechnology company focusing on the development of innovative therapies to address unmet medical needs. The company operates in the biopharmaceutical sector, leveraging cutting-edge scientific research to create novel biologics. Tourmaline Bio is committed to advancing its pipeline of therapeutic candidates through rigorous clinical trials, aiming to deliver transformative treatments to patients worldwide.
Technical Analysis
Lexicon Pharmaceuticals
―
Rezolute
―
Solid Biosciences
―
Opthea Limited Sponsored ADR
―
Terns Pharmaceuticals
―
Ownership Overview
7.98% Insiders
7.30% Mutual Funds
61.52% Other Institutional Investors
14.70% Public Companies and
Individual Investors